RT Book, Section
A1 Metjian, Talene A.
A1 Fisher, Brian
A2 Shah, Samir S.
A2 Kemper, Alex R.
A2 Ratner, Adam J.
SR Print(0)
ID 1157319694
T1 Antifungal Agents
T2 Pediatric Infectious Diseases: Essentials for Practice, 2e
YR 2019
FD 2019
PB McGraw-Hill Education
PP New York, NY
SN 9781259861536
LK accesspediatrics.mhmedical.com/content.aspx?aid=1157319694
RD 2024/04/23
AB The  population  of  immunocompromised  children  at  risk  for  invasive  fungal  disease  continues  to  grow.  This  population  includes  children  with  primary  and  acquired  immune  deficiencies,  recipients  of  solid-organ  and  stem  cell  transplants,  children  with  malignancy  receiving  chemotherapy  agents,  and  those  with  autoinflammatory  or  autoimmune  conditions  receiving  immune-modulating  therapies.  Fortunately,  in  conjunction  with  this  growth,  there  has  been  a  steady  growth  in  the  armamentarium  of  antifungal  agents,  including  development  of  new  classes  of  antifungal  agents  (e.g.,  echinocandins),  as  well  as  newer  generations  of  an  older  antifungal  class,  the  azoles.  Despite  the  increase  in  number  of  antifungal  agents,  the  fungal  pathogens  encountered  in  children  are  variable  and  often  responsive  to  only  a  select  number  of  antifungal  agents.  Coupled  with  the  risk  of  significant  drug–drug  interactions,  therapeutic  options  available  to  a  clinician  for  a  given  clinical  scenario  are  limited.